Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
IPO Year:
Exchange: NASDAQ
Website: incyte.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/3/2025 | $125.00 | Neutral → Buy | Guggenheim |
| 10/8/2025 | Outperform → Perform | Oppenheimer | |
| 8/6/2025 | $89.00 | Equal Weight → Overweight | Wells Fargo |
| 8/1/2025 | $90.00 | Overweight | Barclays |
| 6/16/2025 | $107.00 | Hold → Buy | Stifel |
| 3/18/2025 | Buy → Neutral | Guggenheim | |
| 3/18/2025 | Outperform → Mkt Perform | William Blair | |
| 12/17/2024 | $77.00 | Neutral | UBS |
| 10/29/2024 | $68.00 → $90.00 | Neutral → Buy | BofA Securities |
| 10/1/2024 | $84.00 | Outperform | Wolfe Research |
SCHEDULE 13G - INCYTE CORP (0000879169) (Subject)
144 - INCYTE CORP (0000879169) (Subject)
10-Q - INCYTE CORP (0000879169) (Filer)
8-K - INCYTE CORP (0000879169) (Filer)
8-K - INCYTE CORP (0000879169) (Filer)
144 - INCYTE CORP (0000879169) (Subject)
8-K - INCYTE CORP (0000879169) (Filer)
10-Q - INCYTE CORP (0000879169) (Filer)
8-K - INCYTE CORP (0000879169) (Filer)
144 - INCYTE CORP (0000879169) (Subject)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling
Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy
Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
Submission status for INCYTE CORP's drug PEMAZYRE (SUPPL-1) with active ingredient PEMIGATINIB has changed to 'Approval' on 02/23/2021. Application Category: NDA, Application Number: 213736, Application Classification: Labeling
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Guggenheim upgraded Incyte from Neutral to Buy and set a new price target of $125.00
Oppenheimer downgraded Incyte from Outperform to Perform
Wells Fargo upgraded Incyte from Equal Weight to Overweight and set a new price target of $89.00
Barclays initiated coverage of Incyte with a rating of Overweight and set a new price target of $90.00
Stifel upgraded Incyte from Hold to Buy and set a new price target of $107.00
Guggenheim downgraded Incyte from Buy to Neutral
William Blair downgraded Incyte from Outperform to Mkt Perform
UBS initiated coverage of Incyte with a rating of Neutral and set a new price target of $77.00
BofA Securities upgraded Incyte from Neutral to Buy and set a new price target of $90.00 from $68.00 previously
Wolfe Research initiated coverage of Incyte with a rating of Outperform and set a new price target of $84.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
Fastest customizable press release news feed in the world
Incyte (NASDAQ:INCY) today announced the expansion of its Moments of Clarity program, which amplifies the voices of people living with chronic immune-mediated skin conditions. This year, the initiative introduces six compelling new stories that spotlight the true lived experiences of people living with nonsegmental vitiligo and mild-to-moderate atopic dermatitis (AD), the most common form of eczema. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105709113/en/Opzelura® (ruxolitinitb) cream 1.5% From Sarah, an educator and mom who has lived with vitiligo for more than 17 years, to Adam and his 10-year-old daughter Piper, who fac
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net salesPrelude will continue to develop all JAK2V617F program assets during the option period; if optioned, Incyte would lead development and commercialization globally WILMINGTON, Del., Nov. 04, 2025
INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated data in essential thrombocythemia (ET) and translational data demonstrating disease modifying activity in both ET and MF. Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte's MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in combination with ruxolitinib in GVHD Incyte to host an investor event and webcast highlighting the mutCALR data from the oral presentation at ASH on
Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 am (EST) Jefferies Global Healthcare Conference (London) on Tuesday, November 18, 2025 at 11:00 am (GMT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therap
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory approval and has launched MINJUVI® in Argentina. Knight obtained approval from the Argentinian health regulatory agency, ANMAT, for MINJUVI® (tafasitamab) in combination with lenalidomide, followed by MINJUVI® monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT). DLBCL is the most common subtype of non-Hodgkin lymphoma,
Total revenues of $1.37 billion in the third quarter of 2025, reflecting 20% growth compared to the third quarter of 2024 Jakafi® (ruxolitinib) net product revenue of $791 million, an increase of 7% compared to the same period in 2024 Opzelura® (ruxolitinib) cream net product revenue of $188 million, an increase of 35% compared to the prior year period Hematology-Oncology portfolio net product revenues of $171 million, including Niktimvo™ (axatilimab-csfr) net revenue of $46 million Raises 2025 full year net product revenue guidance to $4.23 - $4.32 billion Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today reported financial results for the t
Collaboration underscores both companies' commitment to advancing patient-centric solutions and expanding access to therapies through novel drug delivery technologies Incyte (NASDAQ:INCY) and Enable Injections, Inc. ("Enable") today announced a new partnership to develop and commercialize specific assets in Incyte's portfolio, including its investigational, first-in-class mutant calreticulin (mutCALR) selective monoclonal antibody, with Enable's enFuse® On-Body Delivery System. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027161257/en/ Under the terms of the agreement, Incyte will obtain a worldwide, exclusive license to
Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) At Week 8, 70% of patients treated with Opzelura achieved a ≥75% improvement in the Eczema Area and Severity Index (EASI75) and 61.3% achieved Investigator's Global Assessment Treatment Success (IGA-TS), co-primary endpoints of the study Based on these results, Incyte expects to file a
This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) INDIANAPOLIS, Oct. 24, 2025 /PRNewswire/ -- New results from Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) showed once-daily, oral baricitinib 4 mg help
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancer Planned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026 Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patients Incyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (NASDAQ:INCY) announced the first clinica
Live finance-specific insights
INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated data in essential thrombocythemia (ET) and translational data demonstrating disease modifying activity in both ET and MF. Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte's MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in combination with ruxolitinib in GVHD Incyte to host an investor event and webcast highlighting the mutCALR data from the oral presentation at ASH on
Total revenues of $1.37 billion in the third quarter of 2025, reflecting 20% growth compared to the third quarter of 2024 Jakafi® (ruxolitinib) net product revenue of $791 million, an increase of 7% compared to the same period in 2024 Opzelura® (ruxolitinib) cream net product revenue of $188 million, an increase of 35% compared to the prior year period Hematology-Oncology portfolio net product revenues of $171 million, including Niktimvo™ (axatilimab-csfr) net revenue of $46 million Raises 2025 full year net product revenue guidance to $4.23 - $4.32 billion Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today reported financial results for the t
Incyte (NASDAQ:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 28, 2025. The schedule for the press release and conference call/webcast is as follows: Q3 2025 Press Release: October 28, 2025 at 7:00 a.m. ET Q3 2025 Conference Call: October 28, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13756261 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers
– Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million] – Opzelura® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $36 million in the second quarter, demonstrating strong commercial execution; raising full year 2025 Other Oncology guidance to a new range of $500 - $520 million [previously $415 - $455 million] – Zynyz® (retifanlimab-
Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13754581 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-6
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit
Late-breaking oral presentation will highlight new data from a trial of INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with essential thrombocythemia (ET) Incyte to host an in-person analyst and investor event highlighting the mutCALR data at EHA on Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 - 1:30 p.m. CEST) Incyte (NASDAQ:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15, 2025, in Milan. "We're looking forward to presenting new data from across our hematology/oncology portfolio at the 20
– Total revenues of $1,053 million in the first quarter (Q1'25) (+20% Y/Y); total product revenues of $922 million in Q1'25 (+26%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to a new range of $2,950 - $3,000 million from $2,925 - $2,975 million – Opzelura® (ruxolitinib) cream net product revenues of $119 million in Q1'25 (+38% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $14 million in the first two months of U.S. launch demonstrating strong commercial execution and high patient need – New, 18-week data from ongoing Phase 3 study of povorcitinib in hidradenitis suppurativa (HS) demonstrates
Incyte (NASDAQ:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q1 2025 Press Release: April 29, 2025 at 7:00 a.m. ET Q1 2025 Conference Call: April 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13753168 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-74
- Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2 Phase 3 studies for both doses tested - Favorable safety profile, with no safety concerns - Data will support planned regulatory submission for povorcitinib in hidradenitis suppurativa (HS) worldwide - Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET Incyte (NASDAQ:INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Both
Live Leadership Updates
Incyte (NASDAQ:INCY) announces that Dave Gardner has been appointed Executive Vice President and Chief Strategy Officer (CSO) effective today, September 22, 2025. In his new role, Mr. Gardner will serve as a key member of the Executive Leadership Team and be responsible for the Company's strategy and business development. "Dave possesses a unique combination of business acumen, scientific knowledge and deep industry experience. His extensive background in biopharma investing will bring a fresh perspective and a focused, judicious approach to corporate development," said Bill Meury, President and Chief Executive Officer, Incyte. "Dave will play a pivotal role in developing a coherent and e
Incyte (NASDAQ:INCY) announces that Soni Basi has been appointed Executive Vice President and Chief Human Resources Officer (CHRO) effective today, August 25, 2025. In her new role, Ms. Basi will serve as a key member of the Executive Leadership Team and be responsible for shaping the Company's global human resources strategy including talent acquisition, organizational design and professional development. "Soni has extensive knowledge and experience in all aspects of human resources," said Bill Meury, President and Chief Executive Officer, Incyte. "She is a skilled professional and collaborative leader who will bring a strategic mindset and operational focus to the company. Soni will pla
- Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO - Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion - Julian Baker elected Chairman of the Board of Directors Incyte (NASDAQ:INCY) today announced that the Company's Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a
Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023. After an extraordinary 27-year career at Novartis in various global roles, including commercialization, market access, investor relations, business development & licensing, acquisitions and company integration, Dr. Schaffert retired in 2022 as President of Novartis Oncology and Member of the Novartis Executive Committee. In that role, Dr. Schaffert ran a global $15 billion business acr
Incyte (NASDAQ:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors. "On behalf of the Incyte Board of Directors, I am happy to welcome Susanne. Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susanne's contributions to our continued growth and future success," said Hervé Hoppenot, Chief Executive Officer, Incyte. "I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need. I look forward to being part of this dynamic Company
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr
Incyte (NASDAQ:INCY) announces the appointment of Otis Brawley, M.D., as a new member of its Board of Directors, effective September 27, 2021. "We are very pleased to welcome Otis to the Incyte Board of Directors. His distinguished career and extensive clinical experience will be a great addition to our Board and we expect he will contribute greatly to our continued success in the future," said Hervé Hoppenot, Chief Executive Officer, Incyte. "As part of the Incyte Board, I join a very experienced and diverse team dedicated to scientific discovery and to the development of new, innovative medicines for patients. I am excited for this opportunity, and look forward to participating in the l
Crescendo Biologics Ltd (Crescendo), a clinical-stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces the appointment of Dr Michael Booth as Chief Financial Officer (CFO). Mike joins with over 20 years' experience in corporate finance within the biopharmaceutical industry. Mike joins Crescendo at an important stage of its development, following the initiation of its Phase Ia/Ib trial for Crescendo's lead Humabody® programme, CB307, a first-in-class PSMA x CD137 T cell enhancer. Mike will be responsible for Crescendo's financial strategy and reporting, as well as global investor relations. Prior to joining Crescendo, Mike served as Division
This live feed shows all institutional transactions in real time.
SC 13G - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)
SC 13G/A - INCYTE CORP (0000879169) (Subject)
SC 13G/A - INCYTE CORP (0000879169) (Subject)
SC 13G/A - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)
SC 13G/A - INCYTE CORP (0000879169) (Subject)
SC 13G/A - INCYTE CORP (0000879169) (Subject)